Importance of provoked spasms at the sites of nonobstructive stenosis as well as at the sites of obstructive stenosis in patients with obstructive coronary arteries and coronary spasm.
Journal
Coronary artery disease
ISSN: 1473-5830
Titre abrégé: Coron Artery Dis
Pays: England
ID NLM: 9011445
Informations de publication
Date de publication:
04 Jun 2024
04 Jun 2024
Historique:
medline:
3
6
2024
pubmed:
3
6
2024
entrez:
3
6
2024
Statut:
aheadofprint
Résumé
There are few reports regarding the prognosis in patients with obstructive coronary artery disease (OCAD) and vasospastic angina (VSA). This study investigated the clinical characteristics and clinical outcomes in patients with VSA and OCAD, especially regarding provoked spasm phenotypes and sites. This was a retrospective, observational, single-center study of 403 patients with typical or atypical angina-like chest pain undergoing acetylcholine (ACH) spasm provocation testing and OCAD. An obstructed coronary artery was defined as ≥50% luminal narrowing. We defined positive epicardial spasm as ≥90% transient stenosis and usual chest symptoms or ischemic ECG changes. Among these 403 patients with OCAD, positive spasm by intracoronary ACH testing was observed in 196 patients (49%), whereas negative spasm was found in the remaining 207 patients (51%). The clinical outcomes in the patients with OCAD and provoked spasm were not different according to the provoked-spasm phenotypes. Furthermore, the clinical outcomes were unsatisfactory in the patients with spasm at the site of nonobstructive lesion alone compared with those with spasm at the site of obstructive and nonobstructive lesions. We should precisely diagnose patients with OCAD who have provoked spasm by using intracoronary ACH testing and medicate the nonobstructive vessels in patients with OCAD and VSA under optimal coronary vasodilators.
Identifiants
pubmed: 38829306
doi: 10.1097/MCA.0000000000001398
pii: 00019501-990000000-00239
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Takagi Y, Yasuda S, Takahashi J, Tsunoda R, Ogata Y, Seki A, et al.; Japanese Coronary Spasm Association. Clinical implications of provocation tests for coronary artery spasm: safety, arrhythmic complications, and prognostic impact: multicentre registry study of the Japanese Coronary Spasm Association. Eur Heart J 2013; 34:258–267.
Yasue H, Takizawa A, Nagao M, Nishida S, Horie M, Kubota J, et al. Long-term prognosis for patients with variant angina and influential factors. Circulation 1988; 78:1–9.
Nishizawa S, Shiraishi J, Torii S, Miyagawa K, Arihara M, Hadase M, et al. Intermediate fixed coronary artery stenosis at the site of ergonovine-provoked spasm as a predictor of long-term major adverse cardiac events of patients with coronary spastic angina. Circ J 2009; 73:699–704.
Sueda S, Ochi N, Kawada H, Matsuda S, Hayashi Y, Tsuruoka T, et al. Frequency of provoked coronary vasospasm in patients undergoing coronary arteriography with spasm provocation test of acetylcholine. Am J Cardiol 1999; 83:1186–1190.
Sueda S, Kohno H, Ochi T, Uraoka T. Overview of the acetylcholine spasm provocation test. Clin Cardiol 2015; 38:430–438.
Sueda S, Mineoi K, Kondo T, Yano K, Ochi T, Ochi N, et al. Absence of induced spasm by intracoronary injection of 50 g acetylcholine in the right coronary artery: usefulness of 80 g of acetylcholine as a spasm provocation test. J Cardiol 1998; 32:155–161.
Sueda S, Kohno H, Miyoshi T, Sakaue T, Sasaki Y, Habara H. Maximal acetylcholine dose of 200 g into the left coronary artery as a spasm provocation test: comparison with 100 g of acetylcholine. Heart Vessels 2015; 30:771–778.
Hokimoto S, Kaikita K, Yasuda S, Tsujita K, Ishihara M, Matoba T, et al.; on behalf of the Japanese Circulation Society and Japanese Association of Cardiovascular Intervention and Therapeutics and Japanese College of Cardiology Joint Working Group. JCS/CVIT/JCC 2023 Guideline focus update on diagnosis and treatment of vasospastic angina (coronary spastic angina) and coronary microvascular dysfunction. Cir J 2023; 87:879–936.
Scanlon PJ, Faxon DP, Audet AM, Leon DL, Carabello B, Murray JA, et al.; ACC/AHA Guidelines for Coronary Angiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography). J Am Coll Cardiol 1999; 33:1756–1824.
Sato K, Kaikita K, Nakayama N, Horio E, Yoshimura H, Ono T, et al. Coronary vasomotor response to intracoronary acetylcholine injection, clinical features, and long-term prognosis in 873 consecutive patients with coronary spasm: analysis of a single-center study over 20 years. J Am Heart Assoc 2013; 2:e000227.
Sueda S, Kurokawa K, Kurokawa T, Sakaue T, Ikeda S. Clinical outcomes and provoked epicardial spasm phenotypes via intracoronary acetylcholine testing in 680 patients with angina and nonobstructive coronary arteries. Life (Basel) 2022; 12:1465.
Nishimiya K, Suda A, Fukui K, Hao K, Takahashi J, Matsumoto Y, et al. Prognostic links between OCT-delineated coronary morphologies and coronary functional abnormalities in patients with INOCA. JACC Cardiovasc Interv 2021; 14:606–618.
Akasaka T, Yoshida K, Hozumi T, Takagi T, Kawamoto T, Kaji S, et al. Comparison of coronary flow reserve between focal and diffuse vasoconstriction induced by ergonovine in patients with vasospastic angina. Am J Cardiol 1997; 80:705–710.
Koyama J, Yamagishi M, Tamai J, Kawano S, Daikoku S, Miyatake K. Comparison of vessel wall morphologic appearance a site of focal and diffuse coronary vasospasm by intravascular ultrasound. Am Heart J 1995; 130:440–445.
Ishii M, Kaikita K, Sato K, Tanaka T, Sugamura K, Sakamoto K, et al. Acetylcholine-provoked coronary spasm at site of significant organic stenosis predicts poor prognosis in patients with coronary vasospastic angina. J Am Coll Cardiol 2015; 66:1105–1115.